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1. Introduction 
The clonal genetic model of cancer defined it as a proliferative disease originating from 
mutated tumour cells. However, not all the cells in a tumour have the same characteristics 
and only particular cells have the capability of originating it. Cancer stem cells (CSCs) and 
cancer initiating cells are the main responsible of this property and are considered, due to 
their characteristics, the actual target for therapy. Moreover, recent evidences indicated that 
these cancer initiating cells are also responsible for the metastatic behaviour of tumours. 
Data obtained in human patients and in mouse models have revealed that CSCs are 
characterized, at the molecular level, by the expression of certain specific markers, a 
complex circuitry of transcriptional and epigenetic regulation, and, in solid tumours, by 
high predisposition to undergo the so called epithelial mesenchymal transition.  
Head and neck squamous cell carcinoma is one of the most prevalent type of malignancy 
worldwide. The mortality due to HNSCC is mainly caused by local recurrence and local 
metastasis to cervical lymph node, and occasionally by distant organ metastasis. The 
primary tumours are characterized by cellular and functional heterogeneity. Numerous 
evidences have indicated the presence of cancer initiating cells or cancer stem cells in this 
type of cancer. Here the current evidences of such cell population in the context of putative 
markers, transcriptional and posttranscriptional regulation, in vivo genetically engineered 
mouse models and possible therapeutic approaches will be reviewed.  
2. Relevance of head and neck cancers  
The term Head and neck cancer comprises several epithelial-derived tumors arising in the 
oral cavity, pharynx, larynx and nasal cavity. The most common type of head and neck 
cancer, including oral cancer, is squamous-cell carcinoma (HNSCC). Head and neck cancers 
represent the sixth most common cancer worldwide, with roughly half million new cases 
each year, and its incidence is still increasing in several geographic areas and its trend is 
now affecting younger individuals (Leemans et al., 2011). Surgery and/or radiation therapy 
remain the gold standards for treatment of cancers of the lip and oral cavity. Recent 
evidence suggests that addition of chemotherapy may provide a survival advantage over 
radiation therapy alone in advanced stages of this disease (Bardet et al., 2011; Calais et al., 
1999; Calais et al., 2004). Despite progress in surgery, radiation, and chemotherapy, the 5-
year survival rate for oral cancer has not improved significantly over the past several 
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decades and remains at about 50–55% (Leemans et al., 2011). As for other types of cancer, 
the main risk factors are alcohol and/or tobacco use (up to 100 times higher for both) 
(Neville and Day, 2002); another important risk factor is HPV infection, which has been 
detected in around 20% of all cases and 50% of oropharynx cases (Leemans et al., 2011). An 
important aspect of these diseases is the significantly increased risk of developing 
subsequent second primary or recurrent tumor which shows similar genetic alterations as 
the original tumor (Braakhuis et al., 2006; Tabor et al., 2002; Tabor et al., 2001). This has led 
to the field cancerization concept (Slaughter et al., 1953), which reflects that premalignant 
clones are present at the surgical margins without macroscopic signs of disease that may 
allow the development of secondary tumors close to the areas where primary tumors arose 
(Bradley et al., 2007; Tabor et al., 2002; Tabor et al., 2001). The development of distant 
metastases, loco-regional recurrence or a second primary tumor cause in many 
circumstances the failure of the treatment, making essential an accurate analysis of the 
origin and spread of the disease. 
As for other types of cancer, HNSCCs show marked heterogeneity affecting cellular 
morphology, proliferative and metastatic index, genetic lesions and therapeutic response. 
Such variability can occur between tumors arising in the same organ (intertumoral 
heterogeneity) identifying distinct tumor subtypes, which are characterized by their 
molecular profile, morphology and expression of specific markers. However, variation is 
also evident within individual tumors (intratumoral heterogeneity), as cells display different 
functional properties and express miscellaneous markers. Such heterogeneity within a single 
tumor is usually a reflection of the hierarchical organization within it. In addition, the 
intratumoral heterogeneity is an indirect indication of the existence of a subpopulation of 
self-renewing cells that can generate the full repertoire of tumor cells. 
3. Cancer initiating vs. cancer stem cells  
For many researchers in basic and translational Oncology the concept “cell of origin” is 
mixed and used interchangeably with the cancer stem cell (CSC) notion. It is important to 
note these two concepts are not necessarily identical (Visvader, 2011). The cell of origin 
refers to the normal cell that acquires the first cancer-promoting mutation(s), whereas, the 
CSC is applied to the cells in the tumor that exclusively sustains the malignant growth. In 
other words, each concept refers to cancer-initiating cells and cancer-propagating cells, 
respectively, two cell populations that substantially differ in their phenotype. However, 
both cell types are also related because the nature of mutations acquired by the cell of origin 
may dictate whether a cancer follows a CSC archetype. The possible reasons for such 
confusing concepts come form the usual way in which CSCs are tested, by injecting or 
implanting into immunocompromissed mice, assuming the minimal number of cells 
required to develop a tumor. In this case both CSCs and initiating cells are the same, but this 
does not indicate that the original tumor initiating cell in the primary tumor was a CSC. 
Also the two current models of tumor evolution and intratumoral heterogeneity source can 
contribute to this confusing aspect: the “cancer stem cell” (CSC) and the “stochastic” or 
“clonal evolution” models. In the first one, the process of tumor growth follows a pattern 
highly similar to that of normal tissues relying on the presence of stem cells, and implicate 
that most tumor cells do not actually contribute to tumor perpetuation, and the 
heterogeneity is due to aberrant differentiation processes from these cancer stem cells. On 
the other hand, in the “clonal evolution model” the self-renewal and tumor maintenance are 
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mediated by the majority of tumor cells, and the differentiation, intraclonal genetic and 
epigenetic variation determine tumor heterogeneity.  Whether which of these models is the 
correct one remains to be elucidated. However, the presence of multiple subclones in a 
single tumor and the identification of putative CSC in a very high proportion (20%) of the 
tumors strongly suggest that the real situation will be a combination of both. Accordingly, 
tumors that evolve through the CSC model, progress on acquiring additional mutations that 
resemble the clonal model. In this regard in, hematological malignancies it has been recently 
reported a tremendous genomic heterogeneity that evolve as clonal branches (Anderson et 
al., 2011; Notta et al., 2011) 
4. Relevant signaling pathways in HNSCC 
As in other solid tumors, the neoplastic process in HNSCC begins with the normal 
epithelium progressing through hyperplasia to dysplasia to carcinoma in situ and invasive 
carcinoma by a multistep process of genetic and epigenetic changes. The earliest 
manifestations of these lesions are leukoplakia or erythroplakia (white or red patches 
observed in the epithelium). The finding that only up to 20% of oral leukoplakias progress 
to malignancy (Braakhuis et al., 2004) indicates that it is possible to treat the disease at this 
premalignant stage. 
As in other cancer types, HNSCC arises through the accumulation of genetic and epigenetic 
changes in genes to acquire a characteristic phenotype that includes limitless replicative 
potential, self-sufficiency in growth signals, insensitivity to anti-growth signals, ability to 
evade apoptosis, invasion and metastasis, and angiogenesis (Hanahan and Weinberg, 2000; 
Negrini et al., 2010). To acquire these properties HNSCC cells need to overcome multiple 
cellular brakes such as those imposed by cell cycle machinery and in particular the p53 and 
Rb-dependent pathways. Somatic mutations in TP53 are found in 60–80% of HNSCC cases 
(Smeets et al., 2011). Moreover, inactivation of p53, either by knock down, by expression of 
dominant-negative mutant p53R172H or by expression of the HPV16 oncoprotein E6, 
conferred extended lifespan on oral keratinocytes (Smeets et al., 2011). Similarly, the 
p16INK4A–cyclin D–CDK4(6)–RB axis is inactive in most HNSCC. In these cases, the 
inactivation is attributable to mutation or methylation in combination with chromosome loss 
or, in most cases, by homozygous deletion of CDKN2A (coding for p16INK4A) and 
amplification of Cyclin D1 locus (occurring in 80% of HNSCC cases). In addition, high-risk 
human papillomavirus (HPV) 16 and 18 infections are also frequent in certain HNSCC 
(Leemans et al., 2011).  In these HPV-associated HNSCC, two oncogenes expressed by the 
HPVs, E7 and E6 target the p53 and the entire Rb family (pRb, p107 and p130) to 
degradation (zur Hausen, 2002). 
Among the different signaling pathways acting in HNSCC, EGFR seems to be crucial. Upon 
binding to its ligands, this receptor triggers activating signals predominantly through the 
Ras–MAPK and PI3K–PTEN–AKT pathways, and may also concur to activate Stat3-
dependent transcription. EGFR is overexpressed in many cases of HNSCC (Grandis and 
Tweardy, 1993; Hama et al., 2009; Ozanne et al., 1986). This results in the clinical use of 
EGFR-specific antibodies in combination with radiotherapy that showed increased efficacy 
to treat HNSCC patients (Bonner et al., 2006). As mentioned, EGFR activation proceeds 
though the PI3K–PTEN–AKT signaling pathway. This is also of extreme relevance in 
HNSCC. Both, activating mutations in PIK3CA as well as inactivating mutations of PTEN, 
have been found in HNSCC. In addition, PIK3CA gains are very frequent in this type of 
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tumors. All these alterations lead to AKT activation. Although the possible presence of 
activating mutations in Akt genes (AKT1, 2 and 3) and gene amplifications remains to be 
confirmed, overall the wide majority of HNSCC display active Akt signaling (Segrelles et al., 
2006). This induces not only resistance to apoptosis, but also facilitates an angiogenic switch 
(Segrelles et al., 2004) and cell proliferation (Paramio et al., 1999). This raised the possibility 
of using anti Akt therapies in HNSCC (Moral and Paramio, 2008). 
5. Identification of putative CSC in HNSCC   
Based on cell surface markers, dye efflux, in vivo tumorigenicity in immunocompromised 
mice, slow-cell cycle progression, upregulation of stemness-related genes, resistance to 
therapy and clonogenic proliferation assays, it has been possible to demonstrate the 
presence of tumor-initiating cells exhibiting stem cell properties in tumors of breast, colon, 
brain and melanoma. All these approaches have been also used to identify the putative ideal 
cancer stem cell marker, which should impart all the acquired hallmarks of self-sufficiency 
in growth signals, anchorage-independent growth, apoptotic/drug resistance, invasiveness, 
metastatic potential and impinge a high self-renewal capacity. However, it is worth noting 
that certain controversies in the experimental systems and the assays followed in these 
characterizations precluded a broad applicability for the cancer stem cell theory in all solid 
tumors. Nonetheless, several cell markers have been used to identify and characterize the 
putative CSCs in HNSCC. 
5.1 CD44  
CD44 is a broadly distributed polymorphic cell surface glycoprotein that mediates 
important processes such as wound healing and tumor metastasis (Naor et al., 2008; Orian-
Rousseau, 2010). Based on its involvement in breast cancer stem cells, several studies have 
analyzed the relevance of CD44 in HNSCCs. In primary HNSCC CD44 expression is 
confined within the basal epithelial cells and is co-expressed with the stem cell-related gene 
BMI-1. The CD44+ cells usually found to be less than 10%, could self-renew indefinitely and 
produce CD44− progeny, and could generate the original tumor heterogeneity after serial 
transplants in NOD/SCID mice (Prince and Ailles, 2008; Prince et al., 2007). Importantly, the 
binding of CD44 to extracellular molecules can drive the activation of PI3K/Akt (Ghatak et 
al., 2005; Gilg et al., 2008; Misra et al., 2005) and MAP kinase and Ras signaling pathways 
(Cheng et al., 2006). However, the CD44+ fraction is probably not a pure population of CSCs 
and, unlike breast CSC, the use of CD44 and CD24 does not appear to further enrich the 
CSC population (Prince and Ailles, 2008; Prince et al., 2007). It is worth mentioning that 
CD44 is actually a family of several proteins that differ in the extracellular domain by 
insertion of variable regions through alternative splicing (Ponta et al., 2003). In particular 
two isoforms CD44s and CD44 v6 are widely expressed in oral epithelia (Mack and Gires, 
2008). However, these proteins were abundantly expressed in carcinomas and also in 
normal tissue (Mack and Gires, 2008) thus indicating that the value of CD44 as a marker for 
a small CSC population in HNSCC needs to be reconsidered.  
5.2 CD133  
This is a 5-transmembrane glycoprotein, also known as Prominin-1 identified in a 
subpopulation of human hematopoietic cells, and has been used for the identification and 
isolation of putative CSCs stem cells from different human tumors such as brain, prostate, 
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colon, liver, pancreas and hematological tumors (Mizrak et al., 2008). Of note, CD133 
expression doe not solely identify these CSC; for instance, in a large series of prostate 
tumors, CD133 is expressed in combination with CD44+ and ǂ2ǃ1hi in approximately 0.1% 
of cells, irrespective of their grade or metastatic state. These cells were capable of self-
renewal, proliferation, and multi-lineage differentiation in vitro to recapitulate the original 
tumour phenotype, consistent with CSC properties (Collins et al., 2005). CD133 expression 
has been found in a small fraction (1-2%) of HNSCC tumors and cell lines (Zhang et al., 
2010). Interestingly this subpopulation of CD133+ cells possess distinct properties 
characteristic of CSCs, including higher potential for clonogenicity, increased expression of 
specific stem cell markers, invasion and in vivo tumorigenicity as well as increased 
chemoresistance as compared with their CD133− counterparts (Zhang et al., 2010). The 
possibility that CD133 is a bona fide CSC for HNSCC however remains to be elucidated in 
wide number of tumor samples.  
5.3 Emmprin 
CD147, also known as EMMPRIN (extracellular matrix metalloproteinase-inducer) TCSF 
(tumor cell-derived collagenase stimulatory factor) and Basigin, is a transmembrane 
glycoprotein that is upregulated during the early stage of premalignant lesions and remains 
stable during invasive and metastatic progression (Vigneswaran et al., 2006). EMMPRIN/ 
CD147 is a major candidate mediating anchorage-independent growth, angiogenesis, drug 
resistance, hypoxic survival and invasion, all of which are essential molecular events of 
carcinogenesis (Vigneswaran et al., 2006). Moreover, its ability to stimulate the production of 
hyaluronan by tumor cells, which in turn promotes cell survival and anchorage-independent 
growth via activation of Akt, Erk and FAK (Marieb et al., 2004), and the fact that it is a CD44 
binding patner may indicate that the combination of CD147/CD44 positive cells may help to 
define a potential subpopulation of CSCs in HNSCC (Richard and Pillai, 2010). 
5.4 The side population (SP)  
The existence of a cell population that exclude the dye Hoechst 33342 was described in bone 
marrow stem cells (Goodell et al., 1997). Subsequently SP cells have also been found in a 
number of other stem cell populations, including putative CSCs for neuroblastoma, 
glioblastoma, breast, cancer and ovarian cancer. Using the same approach Harper et al., 
(Harper et al., 2007) identified a small cell population in HNSCC cell lines. More recently 
Zhang et al., (Zhang et al., 2009) characterized this SP in cell lines and clinical samples of 
HNSCC; they observed that SP+ cells give rise to SP+ and SP-, whereas SP- only produced 
SP- cells. They studied their clonogenic and tumorigenic properties and suggested that these 
cells posses tumor stem cell phenotypes. Moreover, they also observed that these cells 
expressed higher amounts of Bmi1, NSpc1, CD44 and Oct4 together with several members 
of the ABC tansporter family (ABCG2 and ABCB1), thus further reinforcing their 
suggestion. However, although SP+ were clearly more tumorigenic than SP- cells, 104 cells 
are required, a number enough high to exclude that a small subpopulation is the actual 
responsible for tumorigenesis potential.  
5.5 ALDH1  
The aldehyde dehydrogenase (ALDH) families of enzymes are cytosolic isoenzymes that are 
responsible for oxidizing intracellular aldehydes and contributing to the oxidation of retinol 
www.intechopen.com
 
Cancer Stem Cells - The Cutting Edge 
 
76 
to retinoic acid in early stem cell differentiation (Yoshida, 1992). ALDH1 is expressed at 
early stages during HNSCC progression and studies have shown that ALDH1 is a CSCs 
marker and that its presence strongly correlates with tumor malignancy as well as self-
renewal properties of stem cells in different tumors, including breast cancer, hepatoma, 
colon cancer, and lung cancer. Accordingly, ALDH1 cells were isolated from HNSCC 
patients (Chen et al., 2009). These cells showed the ability to form tumorspheres, displayed 
increased migratory properties and demonstrated higher abilities to induce tumor growth 
(Chen et al., 2009). In addition, the expression of ALDH1 correlates with stage and grade of 
tumors and inversely related to poor outcome in HNSCC patients, probably due to an 
increased predisposition to undergo epthelial-mesenchymal transition and increased Snail1 
expression (Chen et al., 2009). Of note, these capacities were more evident in CD44+CD24-
ALDH1+ cells, suggesting that this CD44+CD24-ALDH1+ cell population is likely a CSC in 
human HNSCC. 
5.6 The niche 
Both stem cell maintenance and tumor growth are supported by the stroma. This is not a 
casual event, as in both cases the intricate interrelationship appears to be essential. It is 
worth mentioning that such stroma is composed, in the case of tumors, by a plethora of 
different cells such as fibroblasts and different inflammatory cells. Although there is almost 
no data regarding the niche of oral stem cells, there is mounting evidence that stem cells in 
other stratified epithelia, such epidermis, are supported at least in part by extensive cross 
talk between these cells and their environment (Blanpain and Fuchs, 2009; Fuchs, 2009; 
Moore and Lemischka, 2006). Whether there is a unique microenvironment surrounding 
these progenitors remains to be determined (Moore and Lemischka, 2006). Interestingly, 
cancer stem cells derived from epidermal tumours may exist independently of the classic 
skin stem cell niche, yet also have stem cell properties, including multi-lineage 
differentiation (Ambler and Maatta, 2009). A relative quiescent state is an important feature 
distinguishing adult stem cells. Such quiescence is, in part, directed by external cues 
expressed in the presumptive microenvironment, the niche, although the cellular and 
molecular nature of the niche remains obscure in most SC systems. In turn, this may lead to 
specific restrictive proliferation in the stem cell population (Lopez et al., 2009; Lorz et al., 
2010). Similarly, tumor maintenanace and progression is modulated in part by the 
extracellular matrix and the cells components of the stroma such as fibroblasts (Bhowmick 
and Moses, 2005; Bhowmick et al., 2004b; Kalluri and Zeisberg, 2006), and/or inflammatory 
cells (Andreu et al., 2010; Coussens et al., 1999; Coussens et al., 2000; Kerkela and Saarialho-
Kere, 2003; Spadaro and Forni, 2004; van Kempen et al., 2003). Recently, it has been 
suggested that these cells may affect the tumor growth by specific signaling pathways such 
as TGFǃ (Bhowmick et al., 2004a; Cheng et al., 2005b), HGF/cMet axis (Daly et al., 2008; 
Grugan et al., 2010; Knowles et al., 2009), SDF-1 (Daly et al., 2008; Kojima et al., 2010; Orimo 
et al., 2005), and that the induction of senescence in the stromal cells (Krtolica et al., 2001; 
Liu and Hornsby, 2007; Parrinello et al., 2005; Yang et al., 2006) or the specific inactivation of 
certain pathways such LKB1 (Katajisto et al., 2008) or PTEN (Trimboli et al., 2009) in these 
cells may effectively influence tumor progression. It becomes obvious that such crosstalk 
may also influence CSCs. However, with the clear exception of colon cancer (Borovski et al., 
2011; de Sousa et al., 2011; Vermeulen et al., 2010), the possible effect that the niche can exert 
on this cell population remains unknown.  
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6. Genomics of HNSCC CSC  
6.1 Gene expression studies 
The sequentiation of the human genome and the development of high throughput 
technologies, in particular gene-expression profiling, have provided the opportunity to 
describe biological features, including pathologies, in a quantitative manner. Accordingly, 
there is a astonishing number of genomic studies in cancer, and also the number in HNSCC 
is huge (Braakhuis et al., 2010; Hunter et al., 2005; Molinolo et al., 2009). Subsequently, 
genomics studies of CSCs purified on the basis of cell surface marker have been 
characterized for various tumor types including leukemia, glioblastoma, sarcoma, breast, 
colorectal, lung, pancreatic and prostate cancer. In an early study using quantitative RT-PCR 
analysis performed in CD44+ cells from HNSCC demonstrated an increased expression of 
the stem cell regulator Bmi1 (Prince et al., 2007). Later on, using microarray studies on 
CD44+CD24-ALDH1+ vs CD44+CD24-ALDH1- permitted the identification of 1082 genes 
differentially expressed (Chen et al., 2009). Remarkably among the upregulated genes there 
are stemness genes (OCT4, NANOG, SOX2, KLF4, BMI-1, and NESTIN), Cell cycle 
regulators (CCNA2, GTSE1, MAD2L1, MCM7, RAD21), transcriptional modulators (FOSL1, 
HMGB1, MBNL1, POU5F1, TPX2), modulators of epithelial mesenchymal transition (DKK1, 
SNAI1, SNAI2, TWIST1) and other signaling proteins belonging to mTOR, Cytokine and 
ABC transporter families or pathways (Chen et al., 2009). Importantly the upregulated 
genes included CD147 (Chen et al., 2009). It is therefore conceivable that this genomic study 
may have identified a CD147+CD44+CD24-ALDH1+ population with enriched CSC 
properties.  
6.2 MicroRNA studies 
miRNAs are a class of endogenous non-coding RNAs that function as important regulatory 
molecules by negatively regulating gene and protein expression. They have been implicated 
to control a variety of cellular, physiological, and developmental processes and the aberrant 
expression of miRNAs is connected to human diseases such as cancer acting as a tumor 
suppressors or oncogenes (Brown and Naldini, 2009; Croce, 2008; Croce, 2009; Esteller, 2008; 
Garzon et al., 2009; Garzon et al., 2010; Inui et al., 2010; Ryan et al., 2010). In addition, 
miRNAs are important factors in stem cell function and the expression levels of certain 
miRNAs in stem cells are different from other normal tissues, thus implying that they may 
have a unique role in stem cell regulation (Alvarez-Garcia and Miska, 2005; Cheng et al., 
2005a; Croce and Calin, 2005; Gangaraju and Lin, 2009; Hammond and Sharpless, 2008; 
Sartipy et al., 2009; Wang et al., 2009; Zhang et al., 2006).  The obvious parallelism indicates 
that miRNAs may exert specific roles in self-renewal, proliferation, and differentiation of 
cancer cells including CSCs. In agreement, recent studies have shown involvement of 
several miRNAs in the regulation of CSCs. For example, the miR-200 family inhibits CSC 
functions in breast and pancreatic cancer. Functional inhibitory roles have been suggested 
for miR 125b, miR 183 and miR-34, whereas miR 30 and miR-17-19b may play essential roles 
in maintaining the stem-like features of cancer cells (Croce and Calin, 2005; Inui et al., 2010; 
Wang et al., 2009).  Since there are a relatively large number of studies describing the altered 
expression of miRNAs in HNSCC (Liu et al., 2009; Tran et al., 2010), it is likely that in the 
near future the link between miRNAs and CSCs in HNSCC will find further experimental 
support. 
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7. Mouse models of HNSCC 
The mouse models have proven indispensable in addressing the cellular origin of cancers. 
Two primary approaches have been used to tackle this question in HNSCC. One is based on 
the induction of squamous malignancies by the application of carcinogens to the skin, the so 
called two stage carcinogenesis protocol. The second is a more refined system using 
transgenic or conditionally targeted gene technologies to explore the effects of oncogenes 
and tumour suppressors in different cellular contexts.  
7.1 The two-stage model of mouse skin chemical carcinogenesis  
This system has proved of use in the understanding of the development of squamous 
tumors from a molecular point of view (DiGiovanni, 1992; Slaga et al., 1995; Yuspa, 1998). In 
this model, tumors progress through three sequential steps termed initiation, progression 
and conversion. Initiation is an irreversible and inheritable change that does not lead to 
phenotypic alterations; this can be achieve through the use of dimethylbenzanthracene 
(DMBA), which frequently induces mutations in the Ha-Ras oncogene (Quintanilla et al., 
1986; Zhang et al., 1998). Promotion refers to the selection and expansion of the initiated 
population, giving rise to papillomas; this step is typically induced by the phorbol ester 12-
O-tetradecanoyl-phorbol-13-acetate (TPA). Some of these papillomas proceed through the 
conversion phase, forming malignant squamous cell carcinomas (DiGiovanni, 1992; Slaga et 
al., 1995; Yuspa, 1998). Interestingly, this model displays some parallelisms with certain 
human tumors, including head and neck cancer (Amornphimoltham et al., 2008; 
Amornphimoltham et al., 2004; Segrelles et al., 2006). Such parallelism stands for more than 
a similar pathology or histology. In this system there are two main players that are also 
essential actors in the HNSCC scenario: Akt (Segrelles et al., 2006; Segrelles et al., 2002 
Molinolo et al., 2009) and Stat3 (Kim et al., 2007; Sano et al., 2008). In agreement, deregulated 
Akt activity in transgenic mice leads to heightened sensitivity to this experimental 
carcinogenesis protocol (Segrelles et al., 2007). Accordingly tumors generated through 
injection of Akt-transfected, papilloma derived PB keratinocytes display many molecular 
alterations similar to those found in human HNSCC (Segrelles et al., 2006). The two stage 
chemical carcinogenesis model has allowed the study of the possible role of adult stem cells 
in cancer development (Blanpain and Fuchs, 2006; Blanpain and Fuchs, 2009; Owens and 
Watt, 2003), thus allowing to important aspects of CSC. However, there might be intrinsic 
differences between the epidermal stem cells and oral stem cells. Of note these studies have 
allowed to propose mTOR as a suitable molecule for the treatment of HNSCC targeting 
possibly also CSCs (Amornphimoltham et al., 2008; Amornphimoltham et al., 2005; Castilho 
et al., 2009; Molinolo et al., 2007).  
7.2 Genetically modified mice 
The evolution of gene manipulation techniques in mouse has allow to express or ablate 
virtually any gene, including oncogenes and tumour suppressors, in a target tissue. The 
technical refinement also permits to generate such modification only in a small subsets of 
cells in a tissue in a time controlled manner, thus recapitulating what really happens in 
human sporadic tumors (Jonkers and Berns, 2002; Meuwissen et al., 2001). A number of 
mouse models have tried to recapitulate human HNSCC. The first report of a genetically 
engineered mouse model was the targeted expression of cyclin D1 transgene to the oral-
esophageal epithelium (L2-cyclinD1 transgenic mice) (Nakagawa et al., 1997). These mice 
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exhibited dysplasia in the tongue, esophagus, and forestomach by 16 months of age but did 
not develop tumors (Nakagawa et al., 1997) unless they were crossbred with p53 
heterozygous mice, which resulted in invasive oroesophageal cancer development in  
L2-cyclinD1/p53+/- mice (Opitz et al., 2002). More recently, using inducible systems, it has 
been reported that the activation of an oncogenic K-rasG12D allele in the oral cavity of the 
mouse induces oral tumor formation in mice, but these lesions were classified as benign 
squamous papillomas that progress to squamous malignancy upon activation a point 
mutated p53 gene (Caulin et al., 2007). In contrast, transgenic mice expressing the  
K-ras G12D  oncogene under the control of tet-regulated responsive elements in the basal 
layer of stratified epithelia developed multiple lesions ranging from hyperplasias, 
papillomas, and dysplasias to metastatic carcinomas in the skin and oral mucosa. (Vitale-
Cross et al., 2004). Finally, the TGFǃRII deletion in combination with activation of either K-
ras or H-ras in mouse head-and-neck epithelia caused HNSCC (Lu et al., 2006), in contrast 
with the targeted ablation of this gene in all stratified epithelia, which results in anal and 
genital SCCs (Guasch et al., 2007), indicating that progression to cancers occurs rapidly 
when the TGFǃRII null epithelial tissues are exposed to activated oncogenes and/or loss of 
additional tumor suppressors. Nonetheless, although in many circumstances the transgene 
expression or gene ablation affect the stem cell compartment no careful analysis of this cell 
population or the possible involvement of CSCs have been addressed. Similar to the above 
mentioned models a transgenic mouse model expressing a constitutive active Akt1 kinase 
has been generated. These mice develop spontaneous tumors in various organs and display 
increased sensitivity to two stage skin carcinogenesis protocols (Segrelles et al., 2007). 
Remarkably, these mice also display altered development of several ectodermal organs and 
disturbed homeostasis of the epidermal stem cells (Segrelles et al., 2008). In oral tissues, the 
lesions that these mice develop rarely progress to overt tumors due to induction of 
premature senescence (Moral et al., 2009a). Remarkably genomic analyses in these tissues 
and in primary cells have been used to validate the upregulation of the Kruppel-like factor 4 
(Klf4/Gklf/Ezf) as a potential biomarker for HNSCC (Moral et al., 2009b), in agreement 
with the elevated Klf4 levels found during the early stages of oral squamous-cell carcinomas 
development (Foster et al., 1999) and the induction of squamous epithelial dysplasia by the 
ectopic Klf4 expression in transgenic mice (Foster et al., 2005). Importantly, the ablation of 
the tumor suppressor Trp53 in the same cells that express the active Akt kinase (or the 
ablation of PTEN and p53 genes in these cells) allowed progression of the tumors to 
squamous cell carcinomas that also showed locoregional and distant metastasis, which can 
be followed by imaging in vivo, and display alterations in most of the relevant signaling 
pathways found in human HNSCC (Moral et al., 2009a). Interestingly, both in the tumors in 
vivo and in cell lines derived form these mice, the expression of putative CSC markers 
(CD44, CD133) was noticed along with other stem cell markers (CD34, K15 and ΔNp63) 
(Moral et al., 2009a), thus suggesting that this model can be highly valuable for the 
experimental analysis and characterization of CSCs in HNSCC. 
8. Conclusion  
Overall, although the way leading to the identification of the potential CSCs in HNSCC is 
still long, the achieved findings so far are very promising. Identification of the cell of origin 
in these tumors may allow to the genetic analyses of the lesions involved in tumor initiation 
and progression, thus becoming a unique platform for the identification of early disease 
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biomarkers. In addition, it may have important implications for new preventive therapeutic 
approaches to suppress or reverse the initial phase of disease. On the other hand, the 
identification of CSCs will have a tremendous relevance in the therapy of these tumors. In 
this regard, the available mouse models, and cell lines derived from them, will turn into 
essential tools in uncovering the cellular origins of cancer and the impact of specific 
mutations on tumorigenesis. However, a major disadvantage coming form the inherent 
different systems, human and mouse, makes essential exhaustive validation. Since this is 
particularly achievable using functional and comparative genomics, this potential problem 
can also become a benefit as may allow to the identification of genetic or epigenetic changes 
common in both systems that may permit the identification of suitable targets of potential 
therapeutic benefit.  
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